Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Vincen t Ribrag, Claire N Harrison, DM, FRCP, FRCPath, Florian H Heidel, MD, Jean-Jacques Kiladjian, MD, PhD, Suddhasatta Acharyya, PhD, Song Mu, PhD, Tracy Liu, Denise Williams, MD, Francis J Giles, MB, MD, FRCPI, FRCPath, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Thomas Kindler, MD, Francesco Passamonti, MD, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 4045.

https://doi.org/10.1182/blood.V122.21.4045.4045

Published: 2013

Journal Articles

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Eric Qiong Wu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Denise Williams, MD, Amy Guo, PhD, Diego Ponce de Leon Barido, BA, BS, Andrew Peng Yu, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3841.

https://doi.org/10.1182/blood.V116.21.3841.3841

Published: 2010

Journal Articles

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Andrew Peng Yu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Martin Cloutier, Bsc, Denise Williams, MD

Blood (2010) 116 (21): 4758.

https://doi.org/10.1182/blood.V116.21.4758.4758

Published: 2010

Journal Articles

Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib

Carole Miller, MD, Sikander Ailawadhi, MD, Anand P. Jillella, MD, Jerald P. Radich, MD, Daniel J DeAngelo, MD, PhD, Stuart L Goldberg, MD, Denise Williams, MD, Felice P. Lin, PharmD, Luke Paul Akard, MD

Blood (2010) 116 (21): 2301.

https://doi.org/10.1182/blood.V116.21.2301.2301

Published: 2010

Journal Articles

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

Allen S. Yang, MD, PhD, Anand Jillella, MD, Carole B. Miller, MD, Luke P. Akard, MD, Daniel J. DeAngelo, MD, PhD, Stuart L. Goldberg, MD, Denise Williams, MD, Jerald P. Radich, MD

Blood (2009) 114 (22): 2206.

https://doi.org/10.1182/blood.V114.22.2206.2206

Published: 2009

Journal Articles

Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.

Annie Guerin, MSc, Vamsi K Bollu, PhD, MBA, Denise Williams, MD

Blood (2009) 114 (22): 4285.

https://doi.org/10.1182/blood.V114.22.4285.4285

Published: 2009

Journal Articles

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Magda Tsaneva, BA, Denise Williams, MD, James D Griffin, MD

Blood (2009) 114 (22): 4286.

https://doi.org/10.1182/blood.V114.22.4286.4286

Published: 2009

Journal Articles

Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).

Bayard L. Powell, MD, Hanna Jean Khoury, MD, Jeffrey H. Lipton, David A. Rizzieri, Denise Williams, MD, A. Robert Turner, MD, FRCPC

Blood (2009) 114 (22): 3295.

https://doi.org/10.1182/blood.V114.22.3295.3295

Published: 2009

Journal Articles

The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Marie Cecile Le Deley, Angelo Rosolen, Alfred Reiter, MD, Denise Williams, MD, Keizo Horibe, MD, Grazyna Wrobel, Georg Mann, Jozsef Zsiros, Anne Uyttebroeck, Ildiko Marky, Wolfgang Klapper, Laurence Brugieres

Blood (2008) 112 (11): 577.

https://doi.org/10.1182/blood.V112.11.577.577

Published: 2008

Journal Articles

Compliance with Imatinib Mesylate Associated with Lower Health Resource Utilization and Costs for Patients with CML and GIST.

Rachel Halpern, PhD, Victoria Barghout, MSPH, Denise Williams, MD

Blood (2007) 110 (11): 5159.

https://doi.org/10.1182/blood.V110.11.5159.5159

Published: 2007

Journal Articles

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Laurence Brugières, MD, Marie Cécile Le Deley, MD, Angelo Rosolen, MD, Denise Williams, MD, Ke Horibe, MD, Grazyna Wrobel, MD, Anne Uyttebroeck, MD, Auke Beishuizen, MD, Georg Mann, MD, Karin Mellgren, MD, Alfred Reiter, MD

Blood (2006) 108 (11): 398.

https://doi.org/10.1182/blood.V108.11.398.398

Published: 2006

Journal Articles

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma (ALCL): Results of the European Intergroup Study.

Marie Cécile Le Deley, MD, Laurence Brugières, MD, Denise Williams, MD, Alfred Reiter, MD

Blood (2006) 108 (11): 2050.

https://doi.org/10.1182/blood.V108.11.2050.2050

Published: 2006

Journal Articles

The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.

Shelby D. Reed, PhD, Jasmina I. Radeva, MA, Davey Daniel, MD, John M. Fastenau, MPH, Denise Williams, MD, Kevin A. Schulman, MD

Blood (2004) 104 (11): 234.

https://doi.org/10.1182/blood.V104.11.234.234

Published: 2004

Journal Articles

Early Results Suggest That Epoetin Alfa 60,000 U Every 2 Weeks Improves Hemoglobin in Patients with Cancer Not Receiving Chemotherapy or Radiotherapy.

Daniel Shasha, MD, David H. Henry, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4222.

https://doi.org/10.1182/blood.V104.11.4222.4222

Published: 2004

Journal Articles

Epoetin Alfa 40,000 U QW Increases Hb and Is Safe in Anemic Patients with Cancer Not Receiving Chemotherapy or Radiation Therapy.

Daniel Shasha, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4223.

https://doi.org/10.1182/blood.V104.11.4223.4223

Published: 2004

Journal Articles

Epoetin Alfa 60,000 U SC QW Induction Followed by 60,000 U SC Q2W: Final Study Results of a Novel Treatment Strategy for Chemotherapy-Related Anemia.

Michael Messino, MD, Eric McGary, MD, PhD, Denise Williams, MD.

Blood (2004) 104 (11): 4226.

https://doi.org/10.1182/blood.V104.11.4226.4226

Published: 2004

Journal Articles

Every-Three-Week (Q3W) Maintenance Dosing of Epoetin Alfa in Anemic Cancer Patients Receiving Chemotherapy: 60,000 U SC QW to Target Hb 12 g/dl, Followed by 80,000 U SC Q3W.

Vernon Montoya, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4227.

https://doi.org/10.1182/blood.V104.11.4227.4227

Published: 2004

Journal Articles

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy.

Roger J. Waltzman, MD, Patricia Braly, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4228.

https://doi.org/10.1182/blood.V104.11.4228.4228

Published: 2004

Journal Articles

Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA).

Roger Waltzman, MD, Denise Williams, MD.

Blood (2004) 104 (11): 4233.

https://doi.org/10.1182/blood.V104.11.4233.4233

Published: 2004

NARROW

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).

The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Compliance with Imatinib Mesylate Associated with Lower Health Resource Utilization and Costs for Patients with CML and GIST.

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma (ALCL): Results of the European Intergroup Study.

The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.

Early Results Suggest That Epoetin Alfa 60,000 U Every 2 Weeks Improves Hemoglobin in Patients with Cancer Not Receiving Chemotherapy or Radiotherapy.

Epoetin Alfa 40,000 U QW Increases Hb and Is Safe in Anemic Patients with Cancer Not Receiving Chemotherapy or Radiation Therapy.

Epoetin Alfa 60,000 U SC QW Induction Followed by 60,000 U SC Q2W: Final Study Results of a Novel Treatment Strategy for Chemotherapy-Related Anemia.

Every-Three-Week (Q3W) Maintenance Dosing of Epoetin Alfa in Anemic Cancer Patients Receiving Chemotherapy: 60,000 U SC QW to Target Hb 12 g/dl, Followed by 80,000 U SC Q3W.

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy.

Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only